Conclusions
PREVAIL
(Enzalutamide)
Patients
characterists
Asymtomatic or Minimally
ECOG
0‐1
Older (>75 y)
STRIVE TERRAIN PREVAIL AFFIRM
Population
M0, M1 M1
M1
M1
35%
BPI
≤3
Previous
chemo
NO
NO
NO
YES
Progression on
NOT
NOT
BETTER RESULTS
Visceral disease
Allowed
Blood Pressure
previous
bicalutamide
ALLOWED
ALLOWED ALLOWED ALLOWED
<170/105
Heart Failure Excluded
NYHA 3,4
Atrial fibrillation
Allowed
